A combination of CDK 4/6 inhibition and estrogen receptor antagonists has shown promising results in phase II clinical trials on ER+ advanced endometrial cancer and low-grade serous ovarian carcinoma [49,50]. Here, ESR1 is linked to ovarian serous carcinoma.